Can a Licence Dispute Become a Workable Continuation Plan?

CASI Pharmaceuticals and Acrotech Biopharma: a dialogue on exclusive licensing and commercial reset.

Reference: USG-ACA-DIA-1007-V1.0-EN
Edition: English Version 1.0 · 2026
Language: English
Publisher: USG Academy
Responsible team: USG Academy
Series: Dialogue

About this publication

A structured discussion of the evidence needed for a cure plan, revised commitments or orderly transition before a licence relationship is terminated.

In this publication

Case context
Decision room
Performance evidence
Continuation plan

Published editions retain their reference, version and language record. Revisions are identified as new editions.